Key Highlights
- Shares are up 10.10% pre-market to $3.38, building on a prior close of $3.07.
- The FDA cleared the company's IND application for PM647, a gene-editing therapy targeting Alpha-1 Antitrypsin Deficiency.
- The clearance follows a July arbitration win against Beam Therapeutics that resolved IP rights to the therapy.
Prime Medicine (NASDAQ:PRME) shares are up 10.10% pre-market to $3.38, building on a prior close of $3.07, after the FDA cleared the company's Investigational New Drug application for PM647, an in vivo gene-editing therapy targeting Alpha-1 Antitrypsin Deficiency (AATD). The clearance allows the therapy, designed to correct the E342K mutation in the SERPINA1 gene, to advance into a Phase 1/2, open-label clinical trial. The trial will initially enroll lung-only AATD patients before expanding to those with significant liver disease, with initial data expected in 2027.
The IND clearance marks a meaningful milestone for a company that has yet to generate approved-product revenue, using its proprietary gene-editing platform, which combines a Prime Editor protein with a specialized guide RNA to directly search for and replace targeted DNA sequences, aiming to correct genetic mutations with precision. AATD is a genetic condition that can lead to lung and liver disease, and the company's approach targets the root mutation rather than managing symptoms.
A Legal Win Clears the Path
The FDA clearance comes on the heels of a July arbitration victory against Beam Therapeutics (NASDAQ:BEAM) that resolved intellectual property questions tied to PM647's development. With that dispute settled, the company was able to move forward with regulatory clearance for the therapy, removing a legal overhang that had shadowed the program.
Balancing Pipeline Progress Against Financial Pressure
The stock's pre-market strength stands out against a broader backdrop of investor caution around clinical-stage biotechnology names, particularly amid rising Treasury yields and macroeconomic uncertainty. The company remains a clinical-stage Business with no approved products, generating limited Revenue through collaborations and relying primarily on Equity Financing to fund its diversified pipeline, which spans hematology, immunology, liver, lung, ocular, and neuromuscular disease programs beyond PM647.






Please wait processing your request...